Home › Cancro alla prostata › Ohio
Studi clinici su Cancro alla prostata nello stato di Ohio
65 studi su Cancro alla prostata cercano partecipanti presso sedi nello stato di Ohio.
Città nello stato di Ohio
- Cleveland34 studi
- Columbus24 studi
- Cincinnati18 studi
- Akron9 studi
- Toledo7 studi
- Dayton7 studi
- Youngstown4 studi
- Parma3 studi
- Chillicothe3 studi
Testo ufficiale dello studio (inglese)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Aultman Health Foundation, Canton
- Ohio State University Comprehensive Cancer Center, Columbus
- ProMedica Flower Hospital, Sylvania
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT06931340Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- MetroHealth Medical Center, Cleveland
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 2 ott 2026 · NCT07200830A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- e altri 44
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- MetroHealth Medical Center, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06632977Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
In reclutamentoFase 2
Età 19 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06738303Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- Ohio State University Comprehensive Cancer Center, Columbus
- e altri 22
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT03866382Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamento
Età 18 e oltre · Uomini · Aggiornato il 28 set 2026 · NCT06496256DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07319871A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06136650A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 25 set 2026 · NCT07082920This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 24 set 2026 · NCT07028853Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Central Ohio Urology Group, Gahanna
In reclutamentoFase 2/3
Età da 18 a 100 · Uomini · Aggiornato il 22 set 2026 · NCT06780670A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
- The Ohio State University, Columbus
- Dayton Physicians LLC Dayton, Dayton
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 22 set 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Urology Group - Solaris Network, Cincinnati
- Central Ohio Urology Group, Gahanna
In reclutamentoFase 3
Età da 18 a 100 · Uomini · Aggiornato il 22 set 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Columbus
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 18 set 2026 · NCT06952803A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 17 set 2026 · NCT06925737MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 15 set 2026 · NCT06150417Investigation of Impact of AI on Prostate Cancer Workflow
- Cleveland Clinic Foundation, Cleveland
In reclutamento
Età da 55 a 80 · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07084779Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 15 set 2026 · NCT07493512Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- University Hospitals Cleveland, Cleveland
In reclutamento
Età 18 e oltre · Uomini · Aggiornato il 14 set 2026 · NCT06511141Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Cleveland Clinic Akron General, Akron
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- e altri 27
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 10 set 2026 · NCT05946213A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Solaris Health - The Urology Group, Cincinnati
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 3 set 2026 · NCT07005154A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Gabrail Cancer Center Research, Canton
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 3 set 2026 · NCT07723248The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Cleveland
- Research Site, Dayton
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 26 ago 2026 · NCT07611110Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 21 ago 2026 · NCT04221542A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
In reclutamentoFase 1/2
Età 18 e oltre · Uomini · Aggiornato il 20 ago 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 19 ago 2026 · NCT04423211A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 17 ago 2026 · NCT06842498FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
In reclutamentoFase 1
Età da 18 a 100 · Uomini · Aggiornato il 13 ago 2026 · NCT05519449Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
In reclutamento
Età 19 e oltre · Uomini · Aggiornato il 6 ago 2026 · NCT05610852Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- The Ohio State University, Columbus
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 31 lug 2026 · NCT06613100Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cleveland Clinic Akron General, Akron
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- e altri 15
In reclutamentoFase 3
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT06592924Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 14 lug 2026 · NCT05691465A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- The Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Uomini · Aggiornato il 9 lug 2026 · NCT07103018A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
In reclutamentoStudio osservazionale
Età 18 e oltre · Uomini · Aggiornato il 7 lug 2026 · NCT07406282Fonte: ClinicalTrials.gov, dati recuperati il 4 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.